Monopar Therapeutics
MNPR
10 hedge funds and large institutions have $1.1M invested in Monopar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.31% → 0.3% (-0.01%)
9% less capital invested
Capital invested by funds: $1.21M → $1.1M (-$103K)
23% less funds holding
Funds holding: 13 → 10 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$300K |
| 2 |
BlackRock
New York
|
+$21.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.5K |
| 4 |
Morgan Stanley
New York
|
+$4.58K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$601 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$295K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$77K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$22.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $574K | +$300K | +10,478 | +116% |
|
|
2
Northern Trust
Chicago,
Illinois
| $213K | +$601 | +21 | +0.3% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $169K | +$13.5K | +473 | +9% |
|
|
4
BlackRock
New York
| $89K | +$21.8K | +763 | +34% |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $30K | -$22.9K | -800 | -44% |
|
|
6
Morgan Stanley
New York
| $24K | +$4.58K | +160 | +25% |
|
|
APA
7
American Portfolios Advisors
Holbrook,
New York
| $4.12K | – | – | – |
|
8
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
9
Marshall Wace
London,
United Kingdom
| – | -$295K | -9,531 | Closed |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$77K | -2,496 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$14K | -442 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$4K | -114 | Closed |
|
13
Wells Fargo
San Francisco,
California
| – | +$29 | +1 | +25% |
|
|
PWS
14
Paragon Wealth Strategies
Jacksonville,
Florida
| – | +$344 | +12 | New |
|
MNPR Hedge Fund Activity: Q2 2021 in Review
10 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2021, worth a combined $1.1M — down 8.5% from $1.21M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MNPR and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $300K. The largest seller was Marshall Wace, exiting entirely with an estimated $295K sold.
- 10 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2021, down from 13 in Q1 2021.
- Funds reported $1.1M of Monopar Therapeutics stock for Q2 2021, down 8.5% quarter-over-quarter.
- 1 fund opened new Monopar Therapeutics positions in Q2 2021 and 4 closed out, a net change of -3 holders.
- The largest Monopar Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $300K added.
- The largest Monopar Therapeutics seller in Q2 2021 was Marshall Wace, an estimated $295K sold.
Based on aggregated 13F filings for Q2 2021.